Mehdi Bazrafshan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mehdi Bazrafshan has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Hamed Bazrafshan Drissi
Department of Cardiology, Shiraz University of Medical Sciences, Shiraz, Iran
8 shared publications Maliheh Kamali
Fellow of Echocardiography Cardiologist Shiraz University of Medical Sciences Shiraz Iran
4 shared publications- Ali Akabar Asadi-Pooya
Jefferson Comprehensive Epilepsy Center, Department of Neurology, Thomas Jefferson University, Philadelphia, USA
3 shared publications - Alireza Arzhangzadeh
Department of Cardiology, School of Medicine Shiraz University of Medical Sciences Shiraz Iran
3 shared publications - Alireza Khodadadiyan
Cardiovascular Research Center Shiraz University of Medical Sciences Shiraz Iran
3 shared publications - Hanieh Bazrafshan
Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
3 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (11)
Which Anthropometric Index Best Signals 10‑Year Cardiovascular Risk? A Sex‑Stratified Analysis From the Shiraz Heart Study
Background: Atherosclerotic cardiovascular disease (ASCVD) remains a major global cause of morbidity and mortality, with obesity as a critical contributor. Traditional measures like body mass index (BMI) do not fully capture fat distribution or composition. Anthropometric and fat indices such as body fat (BF), may offer greater precision in ASCVD risk assessment. Methods: We analyzed data from 1106 university individuals (26−72 years). The primary analysis included adults 40−70 years ( n = 761), for whom 10‐year ASCVD risk was estimated using the 2019 ACC/AHA Pooled Cohort Equations (PCE). We modeled continuous risk using sex‐adjusted linear regression with each index entered separately and We tested Index × Sex interactions. Discrimination for elevated risk (≥7.5%) was assessed with ROC/AUC. A secondary analysis in participants p < 0.001). Most participants (73.1%) were classified as low‐risk, though men had greater representation in higher‐risk categories. Furthermore, BF, Waist‐to‐height ratio (WHtR), and Waist‐to‐hip ratio (WHR) showed the strongest positive associations with continuous PCE risk, whereas Fat‐free mass (FFM) was inversely associated ( p < 0.001). For discriminating ≥7.5% risk, WHR performed best, BF and WC were modest and WHtR and BMI provided little to no discriminative ability. Conclusion: Anthropometric indices such as WC, WHR, and BF are valuable discriminators of ASCVD risk, surpassing BMI in risk assessment and stratification.
- 9 November 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (11)
Open AccessWhich Anthropometric Index Best Signals 10‑Year Cardiovascular Risk? A Sex‑Stratified Analysis From the Shiraz Heart Study
Background: Atherosclerotic cardiovascular disease (ASCVD) remains a major global cause of morbidity and mortality, with obesity as a critical contributor. Traditional measures like body mass index (BMI) do not fully capture fat distribution or composition. Anthropometric and fat indices such as body fat (BF), may offer greater precision in ASCVD risk assessment. Methods: We analyzed data from 1106 university individuals (26−72 years). The primary analysis included adults 40−70 years ( n = 761), for whom 10‐year ASCVD risk was estimated using the 2019 ACC/AHA Pooled Cohort Equations (PCE). We modeled continuous risk using sex‐adjusted linear regression with each index entered separately and We tested Index × Sex interactions. Discrimination for elevated risk (≥7.5%) was assessed with ROC/AUC. A secondary analysis in participants p < 0.001). Most participants (73.1%) were classified as low‐risk, though men had greater representation in higher‐risk categories. Furthermore, BF, Waist‐to‐height ratio (WHtR), and Waist‐to‐hip ratio (WHR) showed the strongest positive associations with continuous PCE risk, whereas Fat‐free mass (FFM) was inversely associated ( p < 0.001). For discriminating ≥7.5% risk, WHR performed best, BF and WC were modest and WHtR and BMI provided little to no discriminative ability. Conclusion: Anthropometric indices such as WC, WHR, and BF are valuable discriminators of ASCVD risk, surpassing BMI in risk assessment and stratification.
- Open Access
- 25 September 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (9) , e70471
Antithrombotic Therapy in Coronary Artery Aneurysm, Ectasia, and Slow Flow: A Systematic Review
Background: Coronary artery aneurysm (CAA), coronary artery ectasia (CAE), and coronary slow flow phenomenon (CSFP) are coronary pathologies associated with altered hemodynamics and increased thrombotic risk. However, optimal antithrombotic management remains uncertain because of limited and heterogeneous evidence. Objectives: This systematic review aimed to synthesize data on the efficacy and safety of antiplatelet and anticoagulant therapies in patients with CAA, CAE, and CSFP. Methods: Following PRISMA 2020 guidelines, PubMed, Scopus, Web of Science, and ProQuest were searched through September 2025 for randomized and observational studies evaluating antithrombotic therapy in adults with these conditions. Outcomes included major adverse cardiovascular events and major bleeding. Narrative synthesis was conducted using the SWiM framework. Risk of bias was assessed using ROBINS‐I and RoB 2.0, and certainty of evidence using GRADE. Results: Eleven studies comprising 3271 participants were included: six on CAE ( n = 895), four on CAA ( n = 2356), and one on CSFP ( n = 20). In CAE, dual antiplatelet therapy (DAPT) and oral anticoagulation (OAC) were associated with fewer ischemic events than no therapy, although direct comparisons were inconsistent. The only randomized trial in CAE showed numerically lower recurrent myocardial infarction and cardiovascular death with single antiplatelet therapy (SAPT) plus direct oral anticoagulant (DOAC) versus DAPT, but findings were nonsignificant and based on few events. Evidence for CAA and CSFP remains limited and inconclusive. Conclusions: Intensified antithrombotic therapy may benefit patients with CAE, but evidence remains inconclusive for CAA and CSFP. Large, multicenter randomized trials are warranted to establish condition‐specific treatment recommendations.
- 25 September 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (9) , e70471
Open AccessAntithrombotic Therapy in Coronary Artery Aneurysm, Ectasia, and Slow Flow: A Systematic Review
Background: Coronary artery aneurysm (CAA), coronary artery ectasia (CAE), and coronary slow flow phenomenon (CSFP) are coronary pathologies associated with altered hemodynamics and increased thrombotic risk. However, optimal antithrombotic management remains uncertain because of limited and heterogeneous evidence. Objectives: This systematic review aimed to synthesize data on the efficacy and safety of antiplatelet and anticoagulant therapies in patients with CAA, CAE, and CSFP. Methods: Following PRISMA 2020 guidelines, PubMed, Scopus, Web of Science, and ProQuest were searched through September 2025 for randomized and observational studies evaluating antithrombotic therapy in adults with these conditions. Outcomes included major adverse cardiovascular events and major bleeding. Narrative synthesis was conducted using the SWiM framework. Risk of bias was assessed using ROBINS‐I and RoB 2.0, and certainty of evidence using GRADE. Results: Eleven studies comprising 3271 participants were included: six on CAE ( n = 895), four on CAA ( n = 2356), and one on CSFP ( n = 20). In CAE, dual antiplatelet therapy (DAPT) and oral anticoagulation (OAC) were associated with fewer ischemic events than no therapy, although direct comparisons were inconsistent. The only randomized trial in CAE showed numerically lower recurrent myocardial infarction and cardiovascular death with single antiplatelet therapy (SAPT) plus direct oral anticoagulant (DOAC) versus DAPT, but findings were nonsignificant and based on few events. Evidence for CAA and CSFP remains limited and inconclusive. Conclusions: Intensified antithrombotic therapy may benefit patients with CAE, but evidence remains inconclusive for CAA and CSFP. Large, multicenter randomized trials are warranted to establish condition‐specific treatment recommendations.
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Obesity
- Vol. 2026 (1)
Long‐Term Effects of Orlistat on Lipid Metabolism and Anthropometric Indices: A Meta‐Analysis of Clinical Trials
Background: Orlistat is a potent lipase inhibitor utilized as a preventive agent for obesity and fat absorption control. Existing literature presents conflicting findings regarding its impact on lipid parameters. Methods: This systematic review followed the PRISMA guidelines and was registered in PROSPERO (ID: CRD42024550889). A comprehensive search of PubMed, Scopus, Web of Science, and Cochrane Register of Controlled Trials was conducted for studies published before January 19, 2025. Eligible studies included randomized controlled trials (RCTs) evaluating orlistat in adults (≥ 18 years) with dyslipidemia. Furthermore, the Grading of Recommendations, Assessment, Development, and Evaluations assessment tool was employed to analyze the certainty of evidence or each outcome. Results: A total number of 1369 participants, with 682 in treatment and 687 in control categories, were included in our study. Orlistat reduced body mass index (BMI) (SMD [95% CI]: −0.30 [‐0.58, −0.03], p value (heterogeneity) = 0.026), and also it was associated with a decrease in high‐density lipoprotein cholesterol (SMD (95% CI): −0.31 [‐0.48, −0.13], p value (heterogeneity) = 0.436). Changes in waist circumference (WC) and triglycerides (TGs) did not reach statistical significance in the primary analysis (WC: SMD [95% CI] −0.1562 [‐0.3138; 0.0015], I 2 = 0.0%, p ‐value (heterogeneity) = 0.7572; TG: SMD [95% CI] −0.1668 [‐0.7979; 0.4642], I 2 = 97.7% p value (heterogeneity) < 0.0001); however, after publication‐bias adjustment using the trim‐and‐fill sensitivity analysis, meaningful reductions were discovered for WC (SMD (%95CI): −0.1712 [‐0.3248; −0.0176], I 2 = 0.0%, p value (heterogeneity) = 0.7696) and TG (SMD (%95CI): −0.8900 [‐1.6619; −0.1181], I 2 = 97.9%, p value (heterogeneity) < 0.0001). The secondary analysis demonstrated that follow‐up duration accounted for 30% of TG heterogeneity, suggesting a small but significant decline in orlistat’s TG‐lowering effect over time (slope: −0.1239; 95% CI: −0.2355, −0.0123; p value = 0.0295). No significant changes were observed in other parameters of the study. Besides, gastrointestinal issues were the most frequently reported adverse events among the studies. Conclusion: Our findings suggest that orlistat meaningfully reduces BMI but is associated with decreased HDL‐C, which may be undesirable given HDL‐C’s protective role in cardiovascular health. Evidence for reductions in TG and WC is uncertain: the primary meta‐analysis showed no statistically significant effects, whereas trim‐and‐fill sensitivity analysis suggested potential reductions. No significant short‐term impact on TG was observed, though a modest reduction may emerge with prolonged use.
- 1 January 2026
- Published by Wiley in Journal of Obesity
- Vol. 2026 (1)
Open AccessLong‐Term Effects of Orlistat on Lipid Metabolism and Anthropometric Indices: A Meta‐Analysis of Clinical Trials
Background: Orlistat is a potent lipase inhibitor utilized as a preventive agent for obesity and fat absorption control. Existing literature presents conflicting findings regarding its impact on lipid parameters. Methods: This systematic review followed the PRISMA guidelines and was registered in PROSPERO (ID: CRD42024550889). A comprehensive search of PubMed, Scopus, Web of Science, and Cochrane Register of Controlled Trials was conducted for studies published before January 19, 2025. Eligible studies included randomized controlled trials (RCTs) evaluating orlistat in adults (≥ 18 years) with dyslipidemia. Furthermore, the Grading of Recommendations, Assessment, Development, and Evaluations assessment tool was employed to analyze the certainty of evidence or each outcome. Results: A total number of 1369 participants, with 682 in treatment and 687 in control categories, were included in our study. Orlistat reduced body mass index (BMI) (SMD [95% CI]: −0.30 [‐0.58, −0.03], p value (heterogeneity) = 0.026), and also it was associated with a decrease in high‐density lipoprotein cholesterol (SMD (95% CI): −0.31 [‐0.48, −0.13], p value (heterogeneity) = 0.436). Changes in waist circumference (WC) and triglycerides (TGs) did not reach statistical significance in the primary analysis (WC: SMD [95% CI] −0.1562 [‐0.3138; 0.0015], I 2 = 0.0%, p ‐value (heterogeneity) = 0.7572; TG: SMD [95% CI] −0.1668 [‐0.7979; 0.4642], I 2 = 97.7% p value (heterogeneity) < 0.0001); however, after publication‐bias adjustment using the trim‐and‐fill sensitivity analysis, meaningful reductions were discovered for WC (SMD (%95CI): −0.1712 [‐0.3248; −0.0176], I 2 = 0.0%, p value (heterogeneity) = 0.7696) and TG (SMD (%95CI): −0.8900 [‐1.6619; −0.1181], I 2 = 97.9%, p value (heterogeneity) < 0.0001). The secondary analysis demonstrated that follow‐up duration accounted for 30% of TG heterogeneity, suggesting a small but significant decline in orlistat’s TG‐lowering effect over time (slope: −0.1239; 95% CI: −0.2355, −0.0123; p value = 0.0295). No significant changes were observed in other parameters of the study. Besides, gastrointestinal issues were the most frequently reported adverse events among the studies. Conclusion: Our findings suggest that orlistat meaningfully reduces BMI but is associated with decreased HDL‐C, which may be undesirable given HDL‐C’s protective role in cardiovascular health. Evidence for reductions in TG and WC is uncertain: the primary meta‐analysis showed no statistically significant effects, whereas trim‐and‐fill sensitivity analysis suggested potential reductions. No significant short‐term impact on TG was observed, though a modest reduction may emerge with prolonged use.
- Open Access
- 27 August 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1
Author Correction: Bariatric surgery mitigated electrocardiographic abnormalities in patients with morbid obesity
- 27 August 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1
Open AccessAuthor Correction: Bariatric surgery mitigated electrocardiographic abnormalities in patients with morbid obesity
- Open Access
- 20 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-7
Bariatric surgery mitigated electrocardiographic abnormalities in patients with morbid obesity
Obesity can lead to cardiovascular dysfunctions and cause electrocardiographic disruptions. Bariatric surgery plays a significant role in weight loss. To assess its benefits, this study investigated electrocardiographic changes before and after bariatric surgery. The present article describes a retrospective cohort study with a 6-month follow-up period. Electrocardiograms were interpreted and compared before and six months after surgery. The relationships between weight loss, type of surgery, and electrocardiographic alterations were analyzed. A total of 200 patients participated in the study, with 34 (17%) men and 166 (83%) women. The mean age of the participants was 44.6 ± 8.6, and their mean body mass index was 43.8 ± 5.5 kg/m2. The mean of QTc decreased after the surgery, while the Sokolow-Lyon scores increased. The statistical analysis showed that QTc dispersion (> 40) (P < 0.001), right ventricular hypertrophy (P < 0.001), abnormal R wave progression (P < 0.001), QTc (P < 0.001) and Sokolow-Lyon criteria (P < 0.001) significantly changed postoperatively. In conclusion, bariatric surgery can reduce QTc, correct poor R wave progression, and resolve right ventricular hypertrophy (RVH) in patients with morbid obesity.
- 20 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-7
Open AccessBariatric surgery mitigated electrocardiographic abnormalities in patients with morbid obesity
Obesity can lead to cardiovascular dysfunctions and cause electrocardiographic disruptions. Bariatric surgery plays a significant role in weight loss. To assess its benefits, this study investigated electrocardiographic changes before and after bariatric surgery. The present article describes a retrospective cohort study with a 6-month follow-up period. Electrocardiograms were interpreted and compared before and six months after surgery. The relationships between weight loss, type of surgery, and electrocardiographic alterations were analyzed. A total of 200 patients participated in the study, with 34 (17%) men and 166 (83%) women. The mean age of the participants was 44.6 ± 8.6, and their mean body mass index was 43.8 ± 5.5 kg/m2. The mean of QTc decreased after the surgery, while the Sokolow-Lyon scores increased. The statistical analysis showed that QTc dispersion (> 40) (P < 0.001), right ventricular hypertrophy (P < 0.001), abnormal R wave progression (P < 0.001), QTc (P < 0.001) and Sokolow-Lyon criteria (P < 0.001) significantly changed postoperatively. In conclusion, bariatric surgery can reduce QTc, correct poor R wave progression, and resolve right ventricular hypertrophy (RVH) in patients with morbid obesity.
- Open Access
- 11 March 2024
- Published by Wiley in Clinical Cardiology
- Vol. 47 (3) , e24252
Differentiating electrocardiographic indications of massive and submassive pulmonary embolism: A cross‐sectional study in Southern Iran from 2015 to 2020
Background: Although using electrocardiogram (ECG) for pulmonary embolism (PE) risk stratification has shown mixed results, it is currently used as supplementary evidence in risk stratification. This cross‐sectional study aimed to assess and compare ECG findings of massive and submassive PE versus segmental PE.Methods: This cross‐sectional study included 250 hospitalized patients with a confirmed diagnosis of acute PE from 2015 to 2020 in Southern Iran. Demographic variables, clinical data, troponin levels, on‐admission ECG findings, echocardiography findings, and ECG findings 24 h after receiving anticoagulants or thrombolytics were extracted.Results: Patients diagnosed with submassive or massive PE exhibited significantly higher rates of right axis deviation (p = .010), abnormal ST segment (p < .0001), S1Q3T3 pattern (p < .0001), inverted T wave in leads V1–V3 (p < .0001), inverted T wave in leads V4–V6 (p < .0001), and inverted T wave in leads V1‐V6 (p < .0001). In a multivariable model, inverted T wave in leads V1–V3, inverted T wave in leads V4–V6, pulse rate, and positive troponin test were the statistically independent variables for predicting submassive or massive PE. Furthermore, inverted T wave in leads V1–V3 (sensitivity: 85%, specificity: 95%, accuracy: 93%, AUC: 0.902) and troponin levels (sensitivity: 72%, specificity: 86%, accuracy: 83%, AUC: 0.792) demonstrated the best diagnostic test performance for discriminating submassive or massive PE from segmental PE.Conclusion: In addition to clinical rules, ECG can serve as an ancillary tool for assessing more invasive testing and earlier aggressive treatments among patients with PE, as it can provide valuable information for the diagnosis and risk stratification of submassive or massive PE.
- 11 March 2024
- Published by Wiley in Clinical Cardiology
- Vol. 47 (3) , e24252
Open AccessDifferentiating electrocardiographic indications of massive and submassive pulmonary embolism: A cross‐sectional study in Southern Iran from 2015 to 2020
Background: Although using electrocardiogram (ECG) for pulmonary embolism (PE) risk stratification has shown mixed results, it is currently used as supplementary evidence in risk stratification. This cross‐sectional study aimed to assess and compare ECG findings of massive and submassive PE versus segmental PE.Methods: This cross‐sectional study included 250 hospitalized patients with a confirmed diagnosis of acute PE from 2015 to 2020 in Southern Iran. Demographic variables, clinical data, troponin levels, on‐admission ECG findings, echocardiography findings, and ECG findings 24 h after receiving anticoagulants or thrombolytics were extracted.Results: Patients diagnosed with submassive or massive PE exhibited significantly higher rates of right axis deviation (p = .010), abnormal ST segment (p < .0001), S1Q3T3 pattern (p < .0001), inverted T wave in leads V1–V3 (p < .0001), inverted T wave in leads V4–V6 (p < .0001), and inverted T wave in leads V1‐V6 (p < .0001). In a multivariable model, inverted T wave in leads V1–V3, inverted T wave in leads V4–V6, pulse rate, and positive troponin test were the statistically independent variables for predicting submassive or massive PE. Furthermore, inverted T wave in leads V1–V3 (sensitivity: 85%, specificity: 95%, accuracy: 93%, AUC: 0.902) and troponin levels (sensitivity: 72%, specificity: 86%, accuracy: 83%, AUC: 0.792) demonstrated the best diagnostic test performance for discriminating submassive or massive PE from segmental PE.Conclusion: In addition to clinical rules, ECG can serve as an ancillary tool for assessing more invasive testing and earlier aggressive treatments among patients with PE, as it can provide valuable information for the diagnosis and risk stratification of submassive or massive PE.
- Open Access
- 9 August 2023
- Published by Springer Nature in BMC Medical Education
- Vol. 23 (1) , 1-6
Face-to-face, online, or blended: which method is more effective in teaching electrocardiogram to medical students
Background: Electrocardiogram (ECG) remains an important medical diagnostic and screening tool. This study aimed to compare the effectiveness of online classes instead of traditional face-to-face or blended methods in medical students’ ECG learning.Methods: Two hundred and fifteen medical students (including 105 (48.8%) males and 110 (51.2%) females) were studied from February 2021 to February 2022. Regardless of their grade, participants were divided into three groups: online, face-to-face, and blended. Then all participants sat for an ECG interpretation exam, and their results were compared.Results: Twenty-six (12.1%) participants were residents, and 189 (87.9%) were interns. Thirty-five (16.3%), 85 (39.5%), and 95 (44.2%) participants were taught ECG through face-to-face, online, and blended methods, respectively. Regarding participants’ preferences on teaching methods, 118 (54.9%) preferred face-to-face learning, and the remaining 97 (45.1%) chose online learning (p < 0.001). The blended method seemed more promising in almost half of the exam questions regarding teaching method effectiveness. The mean total exam score was also significantly higher in participants who were taught blended than in the others (7.20 ± 1.89, p = 0.017). Face-to-face (5.97 ± 2.33) and online teaching methods (6.07 ± 2.07) had similar efficacy according to the mean total score (p = 0.819).Conclusion: While most students preferred face-to-face learning to online learning, a blended method seemed more promising regarding students’ skill enhancement to interpret ECG.
- 9 August 2023
- Published by Springer Nature in BMC Medical Education
- Vol. 23 (1) , 1-6
Open AccessFace-to-face, online, or blended: which method is more effective in teaching electrocardiogram to medical students
Background: Electrocardiogram (ECG) remains an important medical diagnostic and screening tool. This study aimed to compare the effectiveness of online classes instead of traditional face-to-face or blended methods in medical students’ ECG learning.Methods: Two hundred and fifteen medical students (including 105 (48.8%) males and 110 (51.2%) females) were studied from February 2021 to February 2022. Regardless of their grade, participants were divided into three groups: online, face-to-face, and blended. Then all participants sat for an ECG interpretation exam, and their results were compared.Results: Twenty-six (12.1%) participants were residents, and 189 (87.9%) were interns. Thirty-five (16.3%), 85 (39.5%), and 95 (44.2%) participants were taught ECG through face-to-face, online, and blended methods, respectively. Regarding participants’ preferences on teaching methods, 118 (54.9%) preferred face-to-face learning, and the remaining 97 (45.1%) chose online learning (p < 0.001). The blended method seemed more promising in almost half of the exam questions regarding teaching method effectiveness. The mean total exam score was also significantly higher in participants who were taught blended than in the others (7.20 ± 1.89, p = 0.017). Face-to-face (5.97 ± 2.33) and online teaching methods (6.07 ± 2.07) had similar efficacy according to the mean total score (p = 0.819).Conclusion: While most students preferred face-to-face learning to online learning, a blended method seemed more promising regarding students’ skill enhancement to interpret ECG.
- 13 November 2021
- Published by Elsevier in Epilepsy Research
- Vol. 178, 106813
Long-term medical and social outcomes of patients with Lennox-Gastaut syndrome
- 13 November 2021
- Published by Elsevier in Epilepsy Research
- Vol. 178, 106813
Long-term medical and social outcomes of patients with Lennox-Gastaut syndrome
- Open Access
- 29 December 2020
- Published by Wiley in Brain and Behavior
- Vol. 11 (3) , e02016
Employment and disability status in patients with functional (psychogenic nonepileptic) seizures
Purpose: We investigated the rate of employment in patients with functional seizures (FS) in a follow‐up study. We also investigated the rate of receiving disability benefits in these patients. Finally, we investigated factors that are potentially associated with their employment status.Methods: In this long‐term study, all patients with FS, who were diagnosed at Shiraz Comprehensive Epilepsy Center, Iran, from 2008 to 2018, were investigated. In a phone call interview to the patients in February 2020, we tried to obtain the following information: seizure outcome, employment status, receiving disability benefits, and their current drug regimen, if any. The first call was made in the evening and after working hours. In case of no response, we made two more attempts in the following weeks to contact the patients during different time periods of the day.Results: Eighty‐ four patients participated. Thirty‐one patients (37%) were employed, and 53 people (63%) were not; at the first visit, the rate of employment was 23%. Female sex (Odds Ratio [OR]: 12.18; 95% Confidence Interval [CI]: 3.51–42.18; p = .0001), taking psychiatric drugs (OR: 4.93; 95% CI: 1.17–20.73; p = .02), and being employed previously (OR: 0.19; 95% CI: 0.04–0.77; p = .02) were independently significantly associated with the current employment status. Three patients (4%) reported receiving disability social benefits, two women and one man.Conclusion: This study highlights that unemployment is a serious issue in patients with FS and psychiatric comorbidities play a significant role in the employment status in these patients.
- 29 December 2020
- Published by Wiley in Brain and Behavior
- Vol. 11 (3) , e02016
Open AccessEmployment and disability status in patients with functional (psychogenic nonepileptic) seizures
Purpose: We investigated the rate of employment in patients with functional seizures (FS) in a follow‐up study. We also investigated the rate of receiving disability benefits in these patients. Finally, we investigated factors that are potentially associated with their employment status.Methods: In this long‐term study, all patients with FS, who were diagnosed at Shiraz Comprehensive Epilepsy Center, Iran, from 2008 to 2018, were investigated. In a phone call interview to the patients in February 2020, we tried to obtain the following information: seizure outcome, employment status, receiving disability benefits, and their current drug regimen, if any. The first call was made in the evening and after working hours. In case of no response, we made two more attempts in the following weeks to contact the patients during different time periods of the day.Results: Eighty‐ four patients participated. Thirty‐one patients (37%) were employed, and 53 people (63%) were not; at the first visit, the rate of employment was 23%. Female sex (Odds Ratio [OR]: 12.18; 95% Confidence Interval [CI]: 3.51–42.18; p = .0001), taking psychiatric drugs (OR: 4.93; 95% CI: 1.17–20.73; p = .02), and being employed previously (OR: 0.19; 95% CI: 0.04–0.77; p = .02) were independently significantly associated with the current employment status. Three patients (4%) reported receiving disability social benefits, two women and one man.Conclusion: This study highlights that unemployment is a serious issue in patients with FS and psychiatric comorbidities play a significant role in the employment status in these patients.